ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Vivos Inc (QB)

Vivos Inc (QB) (RDGL)

0.0559
0.0049
(9.61%)
Closed February 24 04:00PM

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

RDGL News

Press Releases Only

RDGL Discussion

View Posts
lovethatgreen lovethatgreen 2 hours ago
Lol
Bout comes it up
👍️0
CatfishHunter CatfishHunter 2 hours ago
Exactly. Who voluntarily takes a crap everyday in their bed then still sleeps in it? Lmao. They could have sold in December in the high 7s for a small loss, freed up that money equity to scale into something else. Or better they could be averaging down knowing they will make 2-3x+ on submission and likely 10x on approval. But no. Instead they would rather take a dump in their bed, roll around in it everyday and then gripe about the stench. Hilarious!
👍️ 1
Truthsocial Truthsocial 4 hours ago
DEAR OPTIMIST, PESSIMIST, and REALIST, while you guys were arguing about the glass of water, I drank it.
Sincerely,
the OPPORTUNIST

LETS GO DR KORENKO RDGL AND MAYO CLINIC COMING SOON ENOUGH IMO
👍️0
lovethatgreen lovethatgreen 5 hours ago
For a guy that claims they have a 9 cent average you sure talk a lot of shit
👍️ 1 😅 1
mc73 mc73 6 hours ago
Luck does play a part. I wasn't aware of the company when Longhorn bought most of his shares at sub 4 cent levels.
👍️0
CatfishHunter CatfishHunter 8 hours ago
There’s several of us who hold very sizable positions with a good cost average. Don’t call it lucky. I call it intelligent application of DD.
👍️ 2 💯 1
mc73 mc73 18 hours ago
You are one of the lucky few who have not only such a sizable position but also, and critically, a very low cost average.
👍️0
LonghornSean LonghornSean 20 hours ago
Still holding my 10M shares. How about you?
👍️0
konshe konshe 1 day ago
PPS from Red to green on Friday, a good sign RDGL will run very soon. are we ready to enjoy PPS to explode?
👍️ 1 💯 1
konshe konshe 1 day ago
Excellent post , thank you DEN4
👍️ 1
den4 den4 1 day ago
Whahaha… only half empty glass propagandist fake news manipulator SC8 would say something like that keep it true with CNN SC8 facts… lololol
👍️ 2
doccjc doccjc 1 day ago
Hey , that write up said 6 cents not .0535.
What bs. Can’t believe a word of it .

Lololol
👍️0
den4 den4 1 day ago
$RDGL

The Bright Future of Vivos in the Medical Technology Sector 🚀🚀

It’s no exaggeration to say that Vivos (OTCMKTS:RDGL) is turning heads in the medical technology arena. This company, although traded over the counter and priced at a mere six cents per share, is no pump-and-dump scheme straight out of “The Wolf of Wall Street”. In fact, Vivos is making waves with its groundbreaking approach to radiation oncology.

A Revolutionary Approach

Instead of being part of some financial sideshow, Vivos is a radiation oncology specialist with a focus on advanced brachytherapy. This innovative method involves using radioactive materials, particularly yttrium-90, to deliver high-dose treatment directly to the targeted area while minimizing the dosage to surrounding healthy tissue. Brachytherapy is already a promising therapeutic approach, with a projected 7.1% compound annual growth rate (CAGR), poised to reach a value of $1.62 billion by 2030.

A Unique Methodology

What truly sets Vivos apart is its improvement upon brachytherapy through a minimally invasive procedure that employs a hydrogel solution to administer the cancer-fighting therapeutic. Post-implementation, the hydrogel is safely absorbed by the body, marking a significant advancement in the field. Vivos is unique in its brachytherapy-based approach, thereby attracting positive attention from investors who recognize the potential value in this innovative methodology. It’s certainly a step beyond the traditional methods in the industry.

Investor Enthusiasm

An endorsement from a former senior business analyst at Sony Electronics, whose own money is on the line, underlines the optimism surrounding Vivos. Josh Enomoto, the former analyst, has described Vivos as an investment opportunity worth serious consideration. Enomoto’s background in brokering major contracts with Fortune Global 500 companies and providing critical insights for the investment markets makes his endorsement significant. His expression of confidence in Vivos is indicative of the potential he sees in this particular medical technology firm. In this context, it’s worth noting Enomoto’s long position in RDGL, a fact he disclosed in line with publishing guidelines.

Despite being an over-the-counter and a low-volume stock, Vivos has managed to capture the interest of investors and industry professionals. It has positioned itself as a company to watch in the evolving landscape of medical technology, offering potential growth in an innovative and promising sector. Enomoto’s endorsement further solidifies the position of Vivos as an emerging player in the field. It will be interesting to see how the company develops in the coming years, especially considering the growing demand for advanced therapeutic approaches like brachytherapy.

https://wallstreetwaves.com/3-stocks-to-turn-1000-into-1-million-february-2024/
👍️ 3
doccjc doccjc 1 day ago
March 1st one week away . Looking forward to the February monthly update .
IDE submission followed by a probable approval will take care of the share price and all of the FUD posted by the ex employee.
👍️ 3 💯 2
chereb19 chereb19 1 day ago
Enjoy your weekend ..24/7

👍️0
SC8 SC8 1 day ago
For background, RDGL is fairly priced in the 5 cent range given the risk. Dec. offering for more than 4% of company was in the 6 cent range. Retail person buying flea farts atm should reasonably expect to pay less, hence the 5 cent range. Moreover, to close last offering, MK had to renegotiate expiring warrants from previous offerings out to 2027; that says it all. Then there's fact MK failed to get Radiogel to market before the last of original patents expired in 2022, so any mega buyout offer potential is now off the table. That said, RDGL remains a lesser FDA play and people can trade it accordingly if they so wish.

Back to the moment, RDGL is having trouble holding a nickle now because of MK's piss poor management and proven serial lying. Only thing that matters now is getting Radiogel to human trials, and MK has made clear in last few updates, that is his lowest priority. Sadly, IsoPet remains his highest priority and the market doesn't care about IsoPet, as it was launched 5 years ago and never took off.

Those are the facts.
💩 2 🤡 1
konshe konshe 1 day ago
Business are going ahead, but PPS are going down What's the matter? CEO should say somethings. MMs are playing game to steal your cheap shares? or some other reasons? I feel so strange
👍️0
chereb19 chereb19 2 days ago
Did I miss the part of the fantasy where the angry disgruntled ex-employee stopped riding 'free' shares ? That was a fun addition.
👍️0
wrinklesobw wrinklesobw 2 days ago
Lol you’re cute
👍️0
doccjc doccjc 2 days ago
The IDE submission and approval will force the disgruntled ex employee to find another job . It’s coming
👍️ 3 💯 2
SC8 SC8 2 days ago
Stop reading after the big pps lie. People been pumping this loser for years now. Even GS could only pump it for a couple hours on that bogus Dec. 20 BDD news pump and dump. MK has been caught lying too many times about too many things. Then today MK drops another IsoPet turd on Twitter. only to almost immediately take it down. wtf is going on at RDGL?
💩 2 🤡 1 ⛸️ 1
Big Al T Big Al T 2 days ago
I stand corrected.
Five cents.... Don't care if its four.
I still stand by the rest of the article I posted!
👍️ 3
SC8 SC8 2 days ago
Stop the lies. RDGL is currently skimming a nickle/share, not 6 cents. Why claim pps is 20% higher than it is?
💩 2 😴 1 🤡 1
SC8 SC8 2 days ago
We've had guidance from FDA since 2021 after MK wasted his first 5 years before even talking to FDA about human trials, and in those last 3 years, MK has resisted FDA suggestions at every turn, hence why to date he has yet to submitted a single item FDA needs to consider Radiogel for human trials. All facts.
💩 1 🤡 1
Big Al T Big Al T 2 days ago
The Bright Future of Vivos in the Medical Technology Sector

It’s no exaggeration to say that Vivos (OTCMKTS:RDGL) is turning heads in the medical technology arena. This company, although traded over the counter and priced at a mere six cents per share, is no pump-and-dump scheme straight out of “The Wolf of Wall Street”. In fact, Vivos is making waves with its groundbreaking approach to radiation oncology.

A Revolutionary Approach
Instead of being part of some financial sideshow, Vivos is a radiation oncology specialist with a focus on advanced brachytherapy. This innovative method involves using radioactive materials, particularly yttrium-90, to deliver high-dose treatment directly to the targeted area while minimizing the dosage to surrounding healthy tissue. Brachytherapy is already a promising therapeutic approach, with a projected 7.1% compound annual growth rate (CAGR), poised to reach a value of $1.62 billion by 2030.

A Unique Methodology
What truly sets Vivos apart is its improvement upon brachytherapy through a minimally invasive procedure that employs a hydrogel solution to administer the cancer-fighting therapeutic. Post-implementation, the hydrogel is safely absorbed by the body, marking a significant advancement in the field. Vivos is unique in its brachytherapy-based approach, thereby attracting positive attention from investors who recognize the potential value in this innovative methodology. It’s certainly a step beyond the traditional methods in the industry.

Investor Enthusiasm
An endorsement from a former senior business analyst at Sony Electronics, whose own money is on the line, underlines the optimism surrounding Vivos. Josh Enomoto, the former analyst, has described Vivos as an investment opportunity worth serious consideration. Enomoto’s background in brokering major contracts with Fortune Global 500 companies and providing critical insights for the investment markets makes his endorsement significant. His expression of confidence in Vivos is indicative of the potential he sees in this particular medical technology firm. In this context, it’s worth noting Enomoto’s long position in RDGL, a fact he disclosed in line with publishing guidelines.

Despite being an over-the-counter and a low-volume stock, Vivos has managed to capture the interest of investors and industry professionals. It has positioned itself as a company to watch in the evolving landscape of medical technology, offering potential growth in an innovative and promising sector. Enomoto’s endorsement further solidifies the position of Vivos as an emerging player in the field. It will be interesting to see how the company develops in the coming years, especially considering the growing demand for advanced therapeutic approaches like brachytherapy.
👍️ 2 🔥 1
doccjc doccjc 2 days ago
About a week until March, and looking forward to the February update. Keep in mind we have the guidance of the FDA during the IDE process which greatly increases the likelihood of an IDE APPROVAL. Human trials at the Mayo Clinic will follow shortly thereafter. Buckle up.
👍️ 3 💯 2
SC8 SC8 2 days ago
Sad when a pumper has to lie about pps. We're skimming a nickle now.
💩 2 😴 1 🤡 1
Truthsocial Truthsocial 2 days ago
The submission process for some is when senility takes control of their mind and words take the facts guy with a grain of salt....

Who fact checks the fact checkers???

NO ONE.....except mr/ms facts guru
👍️ 2
den4 den4 2 days ago
Yes, we have the February update of course coming and I Expect March / April could be finally our IDE submittal month.. everything comes together in these months and thanks to flexibility of the Breakthrough Device program I do see a approval being granted..


BOOM is on the way !!
👍️ 3
Risk Risk 2 days ago
Den4 hopefully we hear something soon :)) let’s go RDGL and somebody was mentioning smart folks are accumulating:))
👍️ 1
den4 den4 2 days ago
SC8 THE BAGHOLDER IS LOSING IT

HIS AVERAGE IS PROBABLY SOMEWHERE IN THE 0.28 LOLOLOL
🤣 1
den4 den4 2 days ago
"Yes, it’s traded over the counter. Yes, it’s a six-cent stock. No, it’s not something out of the movie “The Wolf of Wall Street.” It's f***ing $RDGL baby! 😱😜🤑

Show some love, #Vivos fans! https://t.co/b6VoZf6scy— Josh Enomoto (@EnomotoMedia) February 22, 2024
👍️ 1
chereb19 chereb19 2 days ago
The ex disgruntled employee is getting a bit angry now. Hopefully they can control their emotions through this difficult times seeing Vivos succeed.
👍️ 2
doccjc doccjc 2 days ago
The submission process you won't be a part of. Same with the approval. Keep posting FUD/BS
👍️0
SC8 SC8 2 days ago
What "submission process"? It's been 8 years. MK wasted 5 years before even approaching FDA about human trials, and in the 3 years since, MK hasn't submitted anything FDA suggested, not a single item. All facts.
💩 3 😴 1 🤡 1
chereb19 chereb19 2 days ago
Yep they must be pissed. Spending their days waiting for twitter alerts in a company they aren't interested in.
👍️0
doccjc doccjc 2 days ago
So glad Dr Korenko cleaned house before embarking upon the IDe process. Imagine having that disgruntled ex employee complaining 24/7 during the submission process.
👍️ 2
SC8 SC8 2 days ago
wtf? They did another IsoPet turd drop on Twitter today and then almost immediately took it down.
💩 2 🤡 1
chereb19 chereb19 2 days ago
Imagine thinking the BDD was fake for a company you hate and an old boss you detest and not reporting it to the FDA.

That would be dumb.

To all you whistleblowers out there..here you go. Knock yourself out

https://www.fda.gov/medical-devices/medical-device-safety/reporting-allegations-regulatory-misconduct
👍️ 1
SC8 SC8 2 days ago
Doesn't matter now if MK is telling truth or not about BDD. What matters is the market doesn't believe him cuz he's lied so many times about so many things. It was a Dec. 20, 2023 pump for a couple hours and then it dumped. That's all. We now know the BDD claim is irrelevant to RDGL volume and pps. It is what it is.
💩 2 😴 1 🤡 1
dshade dshade 2 days ago
Back in the accumulation zone
👍️0
Truthsocial Truthsocial 2 days ago
IRRELEVANT .... YES the skates
👍️0
rickstereo3333 rickstereo3333 2 days ago
Good to know you stand by that utter garbage since many would pretend they never posted something that idiotic.

Gudunya!!!
👍️ 1 💯 1
chereb19 chereb19 2 days ago
Don't worry, they want follow a baggy.
👍️0
mc73 mc73 2 days ago
Never said anyone should.
💤 1 💩 1
chereb19 chereb19 2 days ago
Imagine thinking the BDD was fake for a company you hate and an old boss you detest and not reporting it to the FDA.

That would be dumb.

To all you whistleblowers out there..here you go. Knock yourself out

https://www.fda.gov/medical-devices/medical-device-safety/reporting-allegations-regulatory-misconduct
👍️ 1 💯 1
den4 den4 2 days ago
Awesome post chereb..
👍️ 1
chereb19 chereb19 2 days ago
The power of a BDD.

Firstly, the BDD fast-tracks RadioGel's journey to market. The FDA prioritizes review for these devices, meaning closer interactions, quicker feedback, and potentially a significantly reduced path to market. This is crucial for RadioGel, as it promises a minimally invasive and potentially curative treatment for difficult-to-reach or radiation-resistant tumors.

Beyond speed, the BDD grants RadioGel access to dedicated FDA experts. This fosters open communication, clearer expectations, and streamlined development. Imagine navigating the regulatory process with a roadmap in hand – that's what the BDD offers. This collaborative approach minimizes uncertainties and saves precious resources, propelling RadioGel closer to patients who need it most.

The BDD also acts as a powerful magnet for investors and payers. It's a stamp of approval, highlighting RadioGel's potential to revolutionize cancer treatment. This can facilitate funding and open doors to earlier reimbursement discussions, ensuring wider patient access to this potentially life-saving technology.

Finally, the BDD distinguishes RadioGel in the crowded medical device landscape. It proclaims it as cutting-edge, innovative, and potentially transformative. This market differentiation is invaluable, giving RadioGel a crucial edge in attracting investment, collaborators, and, most importantly, patients who stand to benefit from its unique approach.

In conclusion, RadioGel's BDD is not just a recognition of its potential; it's a powerful engine propelling it towards making a real difference in the lives of cancer patients. The faster development, closer collaboration, and enhanced visibility it brings pave the way for a future where RadioGel's minimally invasive, targeted therapy becomes a beacon of hope for those battling some of the toughest cancers.

Remember, this is just the beginning of RadioGel's journey. With the BDD wind in its sails, it's poised to make waves in the cancer treatment landscape, offering new hope and potentially brighter tomorrows for patients worldwide.




24/7 My fan club
👍️ 1
den4 den4 2 days ago
PRESENTED BY FAKE NEWS SC8 MEDIA
👍️ 1
SC8 SC8 2 days ago
And the relevance to RDGL? It's a claim MK made over two months ago that market either doesn't believe or believes is inconsequential. It was good for a couple hour pump before the dump. There's only one thing that matters now, getting Radiogel to human trials, and per MK, that's his lowest priority right now.
💩 1 🤡 1

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com